Watching RAPHAEL PHARMACEUTICAL INC.? See every signal — funding, hires, M&A, contracts, sentiment.
Book a demoChoose your planFunding, M&A, exec moves and hiring — matched to your market, with the people to call.See plans →
Back to SEC FilingsExecutive ChangeItem 5.02 · 8-KMEDIUM RiskNeutral
RAPHAEL PHARMACEUTICAL INC.
raphaelpharmaceutical.comFiled: Jul 16, 2026CIK: 0001415397Health Care
AI Executive Summary
AI-powered analysis of 8-K filing content
Raphael Pharmaceutical Inc. announced the appointment of Uri Tadelis as Chief Financial Officer effective July 16, 2026, following the immediate resignation of Guy Ofir from the CFO, General Counsel, and Director positions. The company stated the departure was not due to disagreements, indicating a planned management transition.
Key Takeaways
Guy Ofir resigned from three positions (CFO, General Counsel, Director) effective immediately on July 16, 2026
Uri Tadelis was appointed as the new Chief Financial Officer on the same date
2 more takeaways
Filing Overview
Form Type8-K
Filing DateJul 16, 2026
Item5.02
CategoryExecutive Change
CIK0001415397
Accession #0001415397
Risk LevelMEDIUM
SentimentNeutral
Signalinformational
Topics
leadership transitionexecutive departureexecutive hire
What This Means
A senior executive (CEO, CFO, etc.) has joined, departed, or changed roles. Leadership changes can significantly impact strategy.